Zim Laboratories: Palatable Medicine for your Portfolio?

kalidasa · May 8, 2023, 12:57pm

R&D-Oriented Company

Therapy-agnostic delivery solutions and innovative technology platforms that may reduce cost of treatment, improve patient adherence, improve metabolism or offer some other benefits.
- Thinoral: Oral Thin Films (OTF), Mucoadhesive Films
- Taste masking granules
- Liquid in pellets
- Nano particulate granulation
Over 100 people in R&D, around 500 employees
Spent Rs.55.39 crore on R&D in the last three years and plans to maintain R&D expenses in the range of 7% of revenue in the future
40 registered products and 130 products in the pipeline for overseas markets
7 new innovative products developed in the R&D pipeline and another 9 under development expected to be ready in FY24.
Around Rs 400cr market cap (at CMP around Rs 80, 7 May 2023) and around Rs 400cr revenue
Around 72% from pharmaceuticals and 28% from neutraceuticals. 85% of the revenue comes from exports.
The company is focused on harvesting its work on OTF, including 7 patents and partnerships with pharma companies in developed markets. OTF is used for both pharma and neutraceuticals. However, OTF business still is in its infancy considering only Rs 10cr revenue came in FY22.

The global oral thin films market was valued at USD 2.9 billion in 2021 and is projected to grow at 9.3% CAGR from 2022 to 2031.

Financials

Consolidated Results

Balance Sheet

Company Structure

Subsidiaries

SIA ZIM Laboratories Limited, Latvia 100% Subsidiary
- For Registration of products and marketing efforts
  in the EU.
ZIM Laboratories FZE, Sharjah , UAE 100% Subsidiary
- For Business Development and Marketing in MENA
  and Africa Region.
ZIM Health Technologies Limited, India 100% Subsidiary
- For Advisory and Support Services to ZIM on
  overall R&D and Product Development for the
  Pharmerging and Developed Markets.
ZIM Thinorals Private Limited, India 100% Subsidiary
- Created for OTF Business.

Shareholding

Share capital increased to nearly 49 crores after bonus shares issued in Dec 2022
Promoter has around 33%
Among the public shareholders, Mathew Cyriac bought around 22% shares from AA Development Capital Fund in FY22, and Zakir S Vali has around 17.5%.

Risks

Indifferent financial performance so far. Revenue is growing slowly (7% CAGR in the last 5 years).
Low operating margin of around 13%. High R&D spending partially explains this.
Reduced bottomline during the pandemic years suggests that the company has limited pricing power.
Revenue concentration. 5 products contribute 73%, 5 customers contribute 50% in FY22.
Rs 32 cr was spent on bonus shares (Nov 2022) while the company still had more than Rs 60 cr debt (as of Sept 2022). This does not point to prudent financial handling. Furthermore, the number of shares increased to as high as 4.9 crores.
The company has rejected the recent news reports (Apr 2023) that Zim, along with other companies, has received show-cause notice from DGCI.

Preliminary Conclusion

The company seems to have a long runway for growth considering its patent-protected innovations and growing number of partnerships and product registrations. At 15PE, the current valuation is undemanding although not cheap. Will the company be able to grow its revenue at a faster than before pace overall, and particularly in the OTF segment over the new few quarters? A prudent investor would monitor the revenue growth in the company before investing a big sum.

References

Essential

More

Presentation at CPHI 2022–1) Overview of Tech, 2) Posters
Care Ratings Press Release (May 2023)
Company Press Releases
Interview of Promoter (Dec 2022)
- Another interview in Hindi (Mar 2023)
AGM Video (Sept 2022)
- Annual Report

Disclosure

I have a miniscule position in the stock for tracking.

Please do your own research before investing. I am not a registered investment advisor and none of the above constitutes investment advice.

dhruv · June 19, 2023, 6:07am

Any idea on the moats around the business?

Rohit_Sakaria · August 14, 2023, 4:35pm

Q1 FY24 Bad results. Revenue down. Profits evaporated. Pls share your outlook for future from current situation.

gadakalpeshk · August 15, 2023, 3:09pm

https://twitter.com/Investor_Mohit/status/1691355851448000512?t=ih7xbMstZWODyzSl8ZJ-dA&s=19

Nicely explain👍

Kalp_Jain · December 4, 2024, 8:04am

Hi, is anyone tracking this company? Of late the stock is buzzing in trade? Any triggers

kalidasa · December 4, 2024, 9:46am

Most pharma stocks are on fire.
Who knows? Probably this is just the beginning.

VALUE2017 · October 30, 2025, 2:15am

Concal and presentation give good insight on the Company.

Disclosure: Invested at levels of around 72.

VALUE2017 · December 19, 2025, 2:23am

Sub: Press Release for CDSCO approval for Naproxen + Esomeprazole
*** Capsules***
Please find enclosed herewith the Press Release relating to Grant of Permission
to manufacture and market FDC of Naproxen Delayed Release and
Esomeprazole capsule (375mg/500mg + 20mg/ 20mg) received from the Central
Drugs Standard Control Organisation (CDSCO) - Directorate General of Health
Services to the company.

How significant is this approval. Can anybody validate capability of the Company. How is the promoter quality and corporate governance..

Company is looking for raising of funds.

VALUE2017 · February 11, 2026, 4:42pm

ZIM is primarily a formulations company and not an API maker.

ZIM develops and manufactures finished formulations (FF), pre-formulation intermediates (PFIs/DC granules, pellets, taste-masked granules, ready-mix suspensions), and oral thin films (OTF).

Company is basically into 2 segments:

i. Pharmaceutical. (25%)

ii. Nutraceutical. (75%)

Company is an Export oriented unit with around 85% coming from export business, which is commendable for a Company of this size. Majority of the Export sales is however coming from RoW & pharmerging markets, however Company is gradually entering into regulated market of Europe, UK,Portugal, Australia etc.

Zim specializes in Novel Drug Delivery Systems (NDDS). They have developed several proprietary technology platforms designed to improve drug stability, patient adherence, and bioavailability.

New Innovative Product (NIP) Platforms

Zim Labs utilizes four specialized, non-infringing technology platforms for complex generics:

Platform/ Technology Name/ Primary Function

Ø MECT (Micro-Emulsion Coating): Used to solubilize oil-soluble drugs and liquid phases for better absorption.

Ø **PCFT (**Pellet Cold Forming): Designed for heat-sensitive materials that would lose potency at normal processing temperatures.

Ø **RGDRT (**Rapid Gelation Drug Release): Uses fast-forming hydrogels to achieve “pseudo-zero-order” (steady) drug release, serving as an alternative to OROS® technology.

Ø **MAPOTAB (**Matrix Pore Forming Tablet): Creates pores in a tablet matrix to control the release of the drug into aqueous media.

Each of these platforms takes around 5-7 years for development and it is a rare feat for a Company of size Zim lab to have all these capabilities under one roof.

Other platforms developed by the Company:

Oral Thin Films: ZIM’s Patented OTF Platforms: Its flagship patented technology produces rapidly dissolving, non-sticky films that can carry a high drug load (up to 50–60 mg). These are ideal for pediatric and geriatric patients who have difficulty swallowing tablets.

Platform/ Technology Focus/ Key Features & Applications

Thinoral® / Standard OTF/ Their primary patented platform for fast-dissolving oral films. It is non-sticky, non-tacky, and doesn’t “curl” even in high humidity. It can carry drug loads up to 50–100 mg.

Spinoral®/ Nano-OTF/ A combination of Nanotechnology and Thinoral®. It uses nano-carriers to improve the solubility and bioavailability of drugs that are otherwise difficult for the body to absorb.

Printoral®/ Dose Customization/ Focused on precision dosing and personalization. This platform likely utilizes advanced printing/deposition techniques to allow for specific, low-dose concentrations on a single film strip.

ZIM Labs stands out because they solved the “Three Big Problems” of early oral thin films:

Ø Moisture Sensitivity: Their films remain stable and non-sticky even at 70% relative humidity, which is crucial for tropical markets like India and SE Asia.

Ø Drug Loading: Traditional OTFs were limited to very low doses (under 20 mg). ZIM’s technology allows for high-dose APIs (like Sildenafil or Levocetirizine) to be delivered effectively.

Ø Stability & Palatability: They use proprietary Taste Masking and multi-layer casting to ensure that even bitter medications are palatable for children and the elderly.

Advanced Capabilities

Ø Multi-layer Casting: ZIM is one of the few companies capable of manufacturing films with multiple layers, allowing them to combine two incompatible drugs (Combination Therapy) into a single thin strip.

Ø Therapy Agnostic: They have applied these OTF platforms to over 30+ molecules across CNS, Erectile Dysfunction, Anti-emetics, and Vitamins.

MucoStrip® (Mucoadhesive Buccal Films): A platform for sublingual or buccal delivery. It allows drugs to bypass the “first-pass metabolism” (liver processing), leading to faster absorption and higher bioavailability.
Pellets & Multiparticulates: They develop pellets with various release profiles, including immediate, delayed, and sustained release. This allows for precise control over how a drug is released into the system over time.
Taste Masking: A proprietary process used to mask the bitter taste of active ingredients (APIs) without affecting their effectiveness, which is crucial for orally disintegrating strips and dry syrups.
Directly Compressible (DC) Granules: “Tablet-ready” granules that can be easily compressed into finished tablets, reducing manufacturing complexity while maintaining modified-release properties.

The above platforms developed by the Company are “therapy-agnostic,” meaning they are applied across a wide range of medical areas, including:

CNS: Anxiety, epilepsy, and Alzheimer’s.
Cardiovascular: Hypertension and cholesterol management.
Gastrointestinal: Anti-emetics and acidity treatments.
Urology: Bladder control and prostate health.

Company spends around 6% of its sales in R&D which is commendable and has a R&D team size of 96 which is really very impressive.

Company seems to be near inflection as its 12 products are on the verge of commercialisation gradually over a period of 12-18 months. The products due for commercialisation have very good revenue potential and with the pipelines of new products, Company can sustainable generate revenue growth of more then 20 % for next 7-8 years.

Company was earlier having EU GMP approved facilities, however certain critical observations have been made by the auditors in the recent audit. Company has submitted CAPA and is expecting reaudit in current Quarter.

Disclosure : Invested and view are fully biased,

Investment rationale :

Ø With the recent decline during last 6 months, downside seems to be reasonably protected with potential sustainable upside during next 6-12 months.

Ø Company has been regularly conducting concal and it is commendable for a Company with market cap of around Rs 400 Cr.

Ø Company is R&D focussed which is rare in Company of such small size.

Ø Company is making differentiated products and not simple generic product.

Key Monitorable: Successful EU GMP audit with no observation and approval of drugs in regulated market.


Q3 results:

VALUE2017 · May 12, 2026, 3:08am

Company has intimated exchanges regarding completion of EU GMP audit. Hope there are no major or critical observations. If the audit is clean or even with minor observations , it will be a very positive outcome for the Company and it may start its multi year growth journey.

Florintree Trinex Llp												8.91
Elimath Advisors Private Limited						3.37	3.17				11.46	10.44

Veteran investor Cyriac Mathew holds 20% in the Company. He is ex Black Stone and has made investment and generated decent returns in MTAR Technologies, Gokaldas Export etc.

Disclosure : Invested with long term view.